Perform Another (Advanced) Search

1.  Study Posting (5338) Trial #154787, Prostate Cancer, Madison, WI
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

2.  Study Posting (5338) Trial #154786, Prostate Cancer, Seattle, WA
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

3.  Study Posting (5338) Trial #153554, Prostate Cancer, Houston, Tx
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

4.  Study Posting (5338) Trial #153545, Prostate Cancer, Mt. Pleasant, Sc
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

5.  Study Posting (5338) Trial #153556, Prostate Cancer, Greenville, Sc
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

6.  Study Posting (5338) Trial #153551, Prostate Cancer, Upland, Pa
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

7.  Study Posting (5338) Trial #153557, Prostate Cancer, Pittsburgh, Pa
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

8.  Study Posting (5338) Trial #153562, Prostate Cancer, Pittsburgh, PA
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

9.  Study Posting (5338) Trial #153539, Prostate Cancer, Portland, Or
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

10.  Study Posting (5338) Trial #153548, Prostate Cancer, Columbus, Oh
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

11.  Study Posting (5338) Trial #153543, Prostate Cancer, Winston-Salem, Nc
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

12.  Study Posting (5338) Trial #153561, Prostate Cancer, Durham, Nc
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

13.  Study Posting (5338) Trial #153555, Prostate Cancer, Nyack, Ny
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

14.  Study Posting (5338) Trial #153565, Prostate Cancer, New York, Ny
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

15.  Study Posting (5338) Trial #153549, Prostate Cancer, Buffalo, Ny
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

16.  Study Posting (5338) Trial #153558, Prostate Cancer, Albany, Ny
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

17.  Study Posting (5338) Trial #153541, Prostate Cancer, Albany, Ny
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

18.  Study Posting (5338) Trial #153538, Prostate Cancer, Cherry Hill, Nj
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

19.  Study Posting (5338) Trial #153550, Prostate Cancer, Tupelo, Ms
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page

20.  Study Posting (5338) Trial #153546, Prostate Cancer, Jackson, Ms
...or 1 Exclusion Criteria • Active brain or leptomeningeal metastases • Clinically significant cardiovascular disease • Pleural or pericardial effusion • Clinically active second malignancy • Uncontrolled intercurrent illness • Prior cytotoxic chemotherapy, with the exception of estramustine ...
View Page